Merck-Bristol showdown awaits as Keytruda scores in 1st line NSCLC

1 Last

Share
Profile

Follow
coeusthinks

156 Posts.

100

17/06/16

09:56

Post #: 18054387
Share

Merck-Bristol showdown awaits as Keytruda scores in 1st line NSCLC

Merck ($MRK) has chalked up a key win in a new trial for its marketed checkpoint inhibitor Keytruda after it bested chemotherapy and improved overall survival in certain lung cancer patients—but the company now awaits data from its fierce rival Bristol-Myers Squibb’s ($BMY) own first-line trial in Q3.

So good were the apparent data from Merck--which have not yet been shared in detail by the company--that the Data Monitoring Committee has recommended that the trial be stopped, and that those patients receiving chemotherapy in the Keynote-024 study be offered the opportunity to use Merck’s drug.

The trial was assessing Keytruda in patients as a first-line treatment in non-small cell lung cancer (NSCLC) whose tumors expressed high levels of PD-L1 (tumor proportion score of 50% or more).

Expand

.. and the wait for Cavatak/Keytruda STORM Part B results continues.

Last edited by coeusthinks: 17/06/16

VLA Price at posting: $1.10 Sentiment: None Disclosure: Held
8 Upvote

0 Great analysis

Reply

Top Stories

ASX Market Open: Trump's highest-in-a-century tariffs finally go live | Aug 8

HotCopper Highlights Week 32: Lindian hints at gov't REE support; Boss Energy ire & more

LKY

Locksley, Trigg, more: The 10 hot stocks HotCopper users watchlisted in Week 32

IRE

Iress Ltd leads top gainers intraday Friday as Blackstone buyout bid confirmed

What the hell is wrong with ASX Ltd? The hits keep coming, and now CBOE looms

FMG

Fortescue has taken out a first-kind $3B loan from China. Why, exactly, is a good question

VRX

Gov't thumbs up for VRX Silica's Arrowsmith North to get started

RBA's inflation trick: Is the number lying to us?

Week 32 Wrap: Trump tariffs are finally here. Again. But will they even make a sound?

Expert Exchange: Laretive's 4 key strategies to picking ASX winners

1 Last

Add to My Watchlist

What is My Watchlist?

A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.

Merck-Bristol showdown awaits as Keytruda scores in 1st line NSCLC

Top Stories

ASX Market Open: Trump's highest-in-a-century tariffs finally go live | Aug 8

HotCopper Highlights Week 32: Lindian hints at gov't REE support; Boss Energy ire & more

Locksley, Trigg, more: The 10 hot stocks HotCopper users watchlisted in Week 32

Iress Ltd leads top gainers intraday Friday as Blackstone buyout bid confirmed

What the hell is wrong with ASX Ltd? The hits keep coming, and now CBOE looms

Fortescue has taken out a first-kind $3B loan from China. Why, exactly, is a good question

Gov't thumbs up for VRX Silica's Arrowsmith North to get started

RBA's inflation trick: Is the number lying to us?

Week 32 Wrap: Trump tariffs are finally here. Again. But will they even make a sound?

Expert Exchange: Laretive's 4 key strategies to picking ASX winners

Featured News